Harel Gadot - Microbot Medical Chairman of the Board and Presidentident, CEO
| MBOT Stock | USD 0.93 0.05 5.10% |
Chairman
Mr. Harel Gadot is the Chairman of the Board, President, Chief Executive Officer of the Company. He is a cofounder of Microbot Israel and has served as Chief Executive Officer since Microbot Israel was founded in November 2010. He was the Chairman of Microbot Israels Board of Directors since July 2014. He also serves as the Chairman of XACT Robotics Ltd. since August 2013 and MEDX Xelerator LP since July 2016. From December 2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he was responsible for the global strategic marketing of the company. Mr. Gadot also held management positions, as well as leading regional strategic position for Europe, MiddleEast and Africa, as well as in Israel, while at Johnson and Johnson. Mr. Gadot served as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by KimberlyClark Corporation since 2016.
| Age | 51 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 288 Grove Street, Braintree, MA, United States, 02184 |
| Phone | 781 875 3605 |
| Web | https://microbotmedical.com |
Harel Gadot Latest Insider Activity
Tracking and analyzing the buying and selling activities of Harel Gadot against Microbot Medical stock is an integral part of due diligence when investing in Microbot Medical. Harel Gadot insider activity provides valuable insight into whether Microbot Medical is net buyers or sellers over its current business cycle. Note, Microbot Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Microbot Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Harel Gadot over six months ago Acquisition by Harel Gadot of 79567 shares of Microbot Medical at 1.25 subject to Rule 16b-3 |
Microbot Medical Management Efficiency
The company has return on total asset (ROA) of (0.6488) % which means that it has lost $0.6488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3446) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Richard Ferrari | Heartbeam | 70 | |
| Jeffrey MD | Aclarion | 59 | |
Management Performance
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.65 |
Microbot Medical Leadership Team
Elected by the shareholders, the Microbot Medical's board of directors comprises two types of representatives: Microbot Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Microbot. The board's role is to monitor Microbot Medical's management team and ensure that shareholders' interests are well served. Microbot Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Microbot Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rachel Vaknin, Chief Officer | ||
| Harel Gadot, Chairman of the Board and Presidentident, CEO | ||
| Yoseph Bornstein, COFounder Director | ||
| Eyal MD, Chief Board | ||
| MSc MBA, CTO Israel | ||
| Pr DSc, Scientific CoFounder | ||
| Juan DiazCartelle, Chief Officer |
Microbot Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Microbot Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.65 | ||||
| Current Valuation | 12.35 M | ||||
| Shares Outstanding | 16.93 M | ||||
| Shares Owned By Insiders | 1.42 % | ||||
| Shares Owned By Institutions | 7.46 % | ||||
| Number Of Shares Shorted | 565.98 K | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 4.36 X | ||||
| EBITDA | (10.63 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.